Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 15, 2005. The report focuses exclusively on changes in directors' interests in the company's Ordinary Shares and American Depositary Shares (ADSs), including transactions related to the US Retirement Savings Plan, Performance Share Plan Awards, and share option exercises.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document contains only specific transaction prices and share counts related to director compensation and holdings:
- Share Prices: US Retirement Savings Plan average price of $46.67; Option exercise price of $22.067443 per ADS; Option sale average price of $47.7431; UK share sale price of £12.35.
- Share Counts: US Retirement Savings Plan holdings increased from 18,330,144 to 18,374,705 ADSs.
- Director Holdings: Dr. J-P Garnier's total shareholding is 432,663.20 ADSs (including deferred shares).
Material Changes Versus Prior Period
The filing details specific changes in director interests rather than comparative financial performance:
- Retirement Plan: A re-valuation of the cash element in the US Retirement Savings Plan resulted in an increase in notional allocations for Dr. J P Garnier (75 ADSs) and Dr. T Yamada (10 ADSs).
- Performance Share Plan: The three-year performance period (2002-2004) concluded. 50% of awards granted in 2001 vested based on earnings per share growth exceeding the UK Retail Price Index by nine percentage points. The Total Shareholder Return (TSR) condition was not met, so no awards vested under that specific metric.
- Option Exercises: Dr. J-P Garnier exercised options over 79,054 ADSs and sold the same quantity to meet tax liabilities.
Guidance, Outlook, and Management Commentary
The filing text does not provide guidance, outlook, or general management commentary regarding future business strategy or risks. The only performance commentary relates to the vesting of the 2001 Performance Share Plan:
- Performance Conditions: The TSR condition required GSK to rank at least 50th against the FTSE 100 index; this was not achieved. The EPS growth condition was achieved in full.
- Unusual Items: The filing notes that Dr. Garnier's shareholding is equivalent to more than 13 times his annual basic salary.
Important Facts for Investor Verification
- Verify the specific performance metrics used for the 2001 Performance Share Plan vesting, particularly the EPS growth calculation excluding currency and exceptional items.
- Confirm the total number of shares held by Dr. J-P Garnier (432,663.20 ADSs) and the portion deferred under share programs (182,892 ADSs).
- Review the impact of the failed TSR condition on total executive compensation for the 2002-2004 period.
- Note that this filing does not contain consolidated financial results for the period; investors should refer to Form 20-F or quarterly reports for revenue and profit data.